Boston Scientific To Acquire Privately-Held Pain Solutions Developer Nalu Medical For About $533M

Boston Scientific Corporation (BSX) said on Friday that it has entered into a definitive agreement to acquire privately held medical technology company Nalu Medical for an upfront cash payment of approximately $533 million for equity not currently owned by the company.

Nalu is developing minimally invasive solutions for patients with chronic pain, and Boston Scientific has been a strategic investor in the company since 2017.

The transaction is expected to be completed in the first half of 2026, subject to the satisfaction of customary closing conditions. The transaction is not expected to impact Boston Scientific’s adjusted earnings per share (EPS) in 2026. However, the company expects it to be slightly accretive to adjusted EPS in 2027 and increasingly accretive thereafter.

BSX shares traded down 1% in the pre-market session at the time of writing. On Stocktwits, retail sentiment around BSX stock stayed within the ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.

The acquisition is intended to expand the neuromodulation offerings for people living with chronic pain, Boston Scientific said.

"Adding the highly differentiated Nalu Medical technology complements our existing therapies—including spinal cord stimulation, basivertebral nerve ablation and radiofrequency ablation—enabling us to deliver advanced pain relief options to a wider variety of patient populations," President Jim Cassidy said.

Nalu is expected to generate sales of more than $60 million in 2025 and to deliver year-over-year growth of over 25% in 2026.

BSX stock is up by 9% this year and by about 13% over the past 12 months. 

Read also: Bitcoin Falls Below $105,000, Pulling MSTR Lower – XRP And Solana Drop Amid Banking Jitters

For updates and corrections, email newsroom[at]stocktwits[dot]com.

Share

·

Add us on